A Phase I, Open-Label, Single-Dose, Multi-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Subjects With Varying Degrees of Renal Impairment and in Matched Control Subjects With Normal Renal Function
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Gepotidacin (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 09 Jul 2017 Status changed from active, no longer recruiting to completed.
- 07 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 10 May 2017 Planned End Date changed from 1 May 2017 to 26 Jun 2017.